IGM Biosciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

IGM Biosciences (Nasdaq: IGMS), a biotechnology company focused on engineered IgM antibodies, announced that CEO Fred Schwarzer will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:55 p.m. EDT. The event will be held virtually. A live webcast will be accessible on the company’s website, with a replay available for 90 days post-event. This forum highlights IGM's progress since 2010 in overcoming challenges in IgM antibody development.

News Market Reaction – IGMS

-0.32%

-0.32% Session move

In the trading session that priced this news, IGMS declined 0.32%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MOUNTAIN VIEW, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021 at 1:55 p.m. EDT. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of multiple diseases. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

When will IGM Biosciences' CEO speak at the RBC Capital Markets Global Healthcare Conference?

Fred Schwarzer, CEO of IGM Biosciences, will speak at the RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:55 p.m. EDT.

How can I view the IGM Biosciences fireside chat?

You can view the IGM Biosciences fireside chat live on their 'Events and Presentations' page on their website.

What is the focus of IGM Biosciences?

IGM Biosciences is focused on creating and developing engineered IgM antibodies for various diseases.

How long will the IGM Biosciences webcast be available after the event?

The webcast replay will be available on the IGM Biosciences website for 90 days following the presentation.

What advancements has IGM Biosciences made in antibody development?

Since 2010, IGM Biosciences has developed a proprietary IgM technology platform to address manufacturing and protein engineering challenges in IgM antibody therapeutic use.